Niagen Bioscience, Inc. (NAGE)
D
Pipeline Grade
Financial Position (from SEC Filings)
$66.6M
Cash & Equivalents
$1.2M
Quarterly Burn Rate
167 mo
Est. Cash Runway
$270M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-20 | Phase2 Readout | — |
| 2026-09-01 | Phase1 Readout | — |
Active Clinical Trials (15)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05561738 | Nicotinamide Riboside in Ulcerative Colitis | OTHER | Recruiting | 40 |
| NCT05023993 | The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer | OTHER | Active Not Recruiting | 20 |
| NCT06919328 | Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+ | OTHER | Recruiting | 70 |
| NCT07073352 | ACEs, SIRT1, and Premature Vascular Aging in Humans | OTHER | Recruiting | 30 |
| NCT07649161 | Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism | OTHER | Recruiting | 50 |
| NCT07659834 | Food Supplement for Longevity | OTHER | Active Not Recruiting | 18 |
| NCT03821623 | Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adul... | PHASE2 | Recruiting | 118 |
| NCT06032923 | Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabo... | PHASE2 | Recruiting | 78 |
| NCT05732051 | Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients | PHASE2 | Recruiting | 60 |
| NCT04870866 | NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia | PHASE2 | Active Not Recruiting | 13 |
| NCT05703074 | Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid | PHASE2 | Active Not Recruiting | 310 |
| NCT04112641 | NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy | PHASE2 | Active Not Recruiting | 48 |
| NCT04040959 | Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients W... | PHASE2 | Active Not Recruiting | 118 |
| NCT04332341 | Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation | PHASE1 | Recruiting | 20 |
| NCT07251608 | Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus | PHASE1 | Recruiting | 40 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.